March 4, 2023
SAN JOSE, Calif., and UTRECHT, Netherlands, Feb. 13, 2023 – Molecular Devices, LLC., a leading provider of high-performance life science solutions, and...
April 28, 2022
Patients with mutated KRAS (Kirsten rat sarcoma virus) gene account for around 30-50% of the population with colorectal cancer (CRC) and do...
April 28, 2022
Patients with mutated KRAS (Kirsten rat sarcoma virus) gene account for around 30-50% of the population with colorectal cancer (CRC) and do...
November 10, 2021
Our Carla Verissimo, Head of Oncology II speaks about the current challenges of oncology drug development in this exclusive interview of the...
October 11, 2021
Discover how to reduce costly animal experiments and obtain a quick indication of your drug safety with Merel Derksen. Poster 391: Intestinal organoids as in vitro model...
October 6, 2021
Dr. Pourfarzad presents data on the use of HUB Organoids as advanced modes to investigate ADME and safety. Poster 553: HUB Organoids™ improve preclinical toxicology, metabolism, and...
September 24, 2021
HUB presents two posters at the 2021 EUROTOX virtuals congress. Meet the scientists behind the data. Wondering whether you should consider in...
September 10, 2021
Meet our speaker Dr. Sylvia Boj discussing the next-gen models for complex disease modelling. Biopharma Pricing* - Register & Pay By Friday, February 11 & Save Up To...
September 2, 2021
2 September 2021, Utrecht (The Netherlands) - Hubrecht Organoid Technology (HUB) joins a new international consortium of academic and industrial leaders in...
September 1, 2021
New online presentation available on the use of HUB Organoids™ as a revolutionary approach to disease modeling, drug screening, and patient stratification....
August 31, 2021
HUB Organoids derived from patients with chronic hepatitis B show the first molecular signs of liver cancer. The molecular events that drive...
August 18, 2021
VANCOUVER, British Columbia - STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that they have signed an agreement for the use...
August 12, 2021
HUB Organoids™ supports the on-going clinical evaluation of ELX-02 as a therapeutic agent for cystic fibrosis (CF). HUB Organoids™ advance treatment for...
August 5, 2021
Discover the development of a new model to assess drug safety, absorption, methabolism, transport, and permeability. Compromised intestinal barrier function has been...
July 28, 2021
Our CEO Dr. Rob Vries discusses how HUB Organoids help modelling human disease and select best treatement options. Classic in vitro disease...
July 27, 2021
Watch Dr. Sylvia Boj discussing how HUB Organoids accelerate the development of new therapeutics for inflammatory diseases. The lack of preclinical cellular...
July 14, 2021
HUB takes centre stage during this year’s Olympic games in Tokyo by sponsoring the Innovation Parade, an online event organized by the Embassy of the Kingdom of The...
May 18, 2021
Dr. Vries joins the monthly seminar series organized by the Personalized Health Basel (PHB) initiative. Personalized medicine holds great promise for the future of patient treatment, offering the...
April 26, 2021
April 26, 2021 - Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd. (Tokyo:7272) announced today continuation of their collaboration to provide...
July 20, 2020
HUB Organoids as models for precision medicine, in vitro diagnostics, and infectious disease. During this virtual mini-symposium co-hosted with our partner STEMCELL...
May 27, 2020
Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade serous ovarian cancer...
May 13, 2020
Hormone-producing cells in the human gut are difficult to study, as they are very rare and unique to different species of animals....
May 1, 2020
Researchers from the Hubrecht Institute in Utrecht, Erasmus MC University Medical Center Rotterdam, and Maastricht University in the Netherlands have found that...
April 1, 2020
Dear Valued Customer, On Wednesday 11th March the World Health Organization (WHO) declared a pandemic in response to the COVID-19 outbreak. These are...
February 21, 2020
Whereas the CRISPR/Cas9 technology cuts out a defect in a gene and replaces it with a new piece, the latest CRISPR technology...
December 10, 2019
On December 10, 2019 the Financial Times featured HUB Organoids™ in an article titled “Organoid innovation offers potential for cancer research". Prof....
October 17, 2019
San Diego, October 17, 2019 – Crown Bioscience today announced the launch of a new tumor organoid drug development platform with the...
October 1, 2019
Leiden, Utrecht September 2019 - MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into a strategic collaboration to market organoid...
July 16, 2019
Manchester, 16th July, 2019 - Epistem Limited, the UK based pre-clinical and clinical research services company announces the expansion of its in...
May 19, 2019
San Diego, Calif – May 19, 2020 — Crown Bioscience today announced the expansion of their unique organoid platform with the addition of 130 Hubrecht Organoid Technology...
April 9, 2019
March 27, 2019 – Hubrecht Organoid Technology (HUB) and JSR Corporation, the parent company, of Crown Bioscience, entered into a strategic partnership...
February 1, 2019
February 1, 2019 – Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd. (Tokyo:7272) announced today their collaboration to provide solutions that...
